Straits Times Index
3,338.57 +5.77 (+0.17%) S&P 500
5,475.09 +14.61 (+0.27%) Dow
39,169.52 +50.66 (+0.13%) Nasdaq
17,879.30 +146.70 (+0.83%) Bitcoin USD
63,005.61 +1,006.79 (+1.62%) CMC Crypto 200
1,347.15 +45.08 (+3.46%)
VSTM Jul 2024 5.000 put
- Business Wire
Verastem Oncology Announces Addition to Russell 3000® and Russell Microcap® Indexes
BOSTON, July 01, 2024--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that in connection with the 2024 Russell U.S. Indexes annual reconstitution, the company will be added to the Russell 3000® and Russell Microcap® Indexes, effective at the open of U.S. equity markets today, Monday, July 1, 2024.
- Zacks
Verastem (VSTM) Up on Upbeat Early Pancreatic Cancer Study Data
Verastem (VSTM) gains 57% post-market on achieving a confirmed partial response in 83% of first-line patients treated with novel combo therapy in the initial cohort of its phase I/II pancreatic cancer study.
- Benzinga
What's Going On With Mid-Cap Cancer-Focused Verastem Oncology Stock On Friday?
Thursday, Verastem Oncology (NASDAQ:VSTM) announced the initial interim safety and efficacy results from the ongoing RAMP 205 Phase 1/2 trial evaluating avutometinib plus defactinib in combination with gemcitabine and Nab-paclitaxel in the first-line in patients with metastatic pancreatic cancer. The initial interim results will be presented at the upcoming American Society of Clinical Oncology Annual Meeting. As of May 14, patients receiving the combination of avutometinib and defactinib with g
